Association for the Advancement of Wound Care - Professional Services

Announcement of coverage for autologous blood-derived products for the treatment of chronic wounds

Medicare announced on August 2nd the conditions under which Medicare will be provide coverage for autologous blood-derived products for the treatment of chronic wounds.

CMS issued the National Coverage Determination: Decision Memorandum for CAG-00190R3 – Autologous Blood-Derived Products for Chronic Non-Healing Wounds. Link provided below.

CMS will cover autologous platelet-rich plasma (PRP) only for patients who have chronic non-healing diabetic, pressure, and/or venous wounds and when all the following conditions are met:

  •     The patient is enrolled in a clinical research study that addresses the specific questions using validated and reliable methods of evaluation.
  •     Clinical study applications for coverage pursuant to this National Coverage Determination (NCD) must be received by August 2, 2014.
  •     The clinical research study meets specific requirements identified in the Decision Memo.

Detailed information on Decision Memorandum for CAG-00190R3 is available here.